Search

Displaying results 381 - 390 of 2454 in total
  1. Drug

    PD-173952

    go.drugbank.com/drugs/DB17041
    Experimental

    PD-173952 is a potent Myt1 kinase inhibitor.[A253067]

  2. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  3. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody por...

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  4. Drug

    Indigotindisulfonic acid

    go.drugbank.com/drugs/DB11577
    ApprovedInvestigational

    This compound is an acid-base indicator and is used in the production of food colorants and pH tests.

  5. Drug

    PB-722

    go.drugbank.com/drugs/DB18447
    Experimental

    PB-722 is a long-acting glucagon receptor agonist.[L48260]

  6. Drug

    Secretin human

    go.drugbank.com/drugs/DB09532
    ApprovedInvestigational

    The main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. … The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 [L1875].

  7. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  8. Drug

    PF-03758309

    go.drugbank.com/drugs/DB11775
    Investigational

    PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.

    Salts: Pf 03758309 Hydrochloride
  9. Drug

    PF-06273340

    go.drugbank.com/drugs/DB12269
    Investigational

    Pf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects

  10. Drug

    PF-07799933

    go.drugbank.com/drugs/DB17489
    Investigational

    PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.